Grant J, Blicker M, Piquette-Miller M, Allen C
Department of Pharmaceutical Sciences, University of Toronto, 19 Russell Street, Toronto, Ontario, M5S 2S2 Canada.
J Pharm Sci. 2005 Jul;94(7):1512-27. doi: 10.1002/jps.20379.
Chitosan and egg phosphatidylcholine (ePC) were used as a unique combination to prepare composite films for localized drug delivery. In comparison to other phospholipids analyzed, ePC was found to produce chitosan-based films with minimal swelling and a high degree of stability. The properties of the chitosan-ePC films were characterized and found to be dependent on the ratio of chitosan:ePC present. FTIR analysis of chitosan-ePC films revealed that their high stability may be attributed to interactions present between these two biomaterials. In vitro evaluation of the cytotoxicity and protein adsorption properties of the films were used to provide a preliminary indication of their biocompatibility. The chitosan-ePC film was also evaluated as a matrix for the localized delivery of the anti-cancer agent, paclitaxel. Nanoparticles containing paclitaxel were dispersed throughout the chitosan-ePC film to result in a drug:material ratio of 1:8 (wt/wt). The film was found to provide a sustained release of paclitaxel over a 4-month period in biologically relevant media. The biological activity of paclitaxel loaded in the chitosan-ePC film was confirmed in SKOV-3 human ovarian cancer cells.
壳聚糖和鸡蛋卵磷脂（ePC）被用作一种独特的组合来制备用于局部药物递送的复合膜。与分析的其他磷脂相比，发现ePC能制备出溶胀最小且稳定性高的壳聚糖基膜。对壳聚糖 - ePC膜的性能进行了表征，发现其取决于壳聚糖与ePC的比例。壳聚糖 - ePC膜的傅里叶变换红外光谱（FTIR）分析表明，其高稳定性可能归因于这两种生物材料之间的相互作用。对膜的细胞毒性和蛋白质吸附特性进行体外评估，以初步表明其生物相容性。壳聚糖 - ePC膜还被评估为抗癌药物紫杉醇局部递送的基质。含紫杉醇的纳米颗粒分散在整个壳聚糖 - ePC膜中，使药物与材料的比例达到1:8（重量/重量）。发现在生物相关介质中，该膜能在4个月的时间内持续释放紫杉醇。在SKOV - 3人卵巢癌细胞中证实了负载在壳聚糖 - ePC膜中的紫杉醇的生物活性。
